Open, Multicentre,Randomized Phase IV Trial to Evaluate Efficacy/Safety to Extend Treatment Duration With Peginterferon Alfa-2a+High Dose of Ribavirin Supporting Epo beta in Treatment of CHC in HIV-HCV Patients Who Not Clear Virus at Week 4
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms PERICO
- 08 Nov 2011 Results presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.
- 02 Mar 2011 Interim results presented at the 18th Conference on Retroviruses and Opportunistic Infections.
- 22 Jul 2009 Results of a ribavirin pharmacokinetic substudy presented at the 5th International AIDS Society (IAS) conference on HIV Pathogenesis, Treatment and Prevention.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History